In this regard, further studies are recommended in order to precisely evaluate the efficacy and safety of anti-TNF-α and anti-IL-6 drugs in the management of FMF severity and complications, mainly amyloidosis, among children. The gene discussed is IL6; the disease is amyloidosis.